US 11,654,165 B2
Airway medicaments
David S. Harburger, Carlisle, MA (US); and Prashant Girinath, Arlington, MA (US)
Assigned to Trench Therapeutics, Inc., Portola Valley, CA (US)
Filed by Trench Therapeutics, Inc., Portola Valley, CA (US)
Filed on Nov. 12, 2021, as Appl. No. 17/524,923.
Application 17/524,923 is a continuation of application No. PCT/US2021/034464, filed on May 27, 2021.
Claims priority of provisional application 62/704,770, filed on May 28, 2020.
Prior Publication US 2022/0072072 A1, Mar. 10, 2022
Int. Cl. A61K 35/741 (2015.01); A61K 35/00 (2006.01); A61M 15/00 (2006.01); A61M 15/08 (2006.01); A61K 35/747 (2015.01)
CPC A61K 35/747 (2013.01) [A61K 35/741 (2013.01); A61K 2035/115 (2013.01); A61M 15/009 (2013.01); A61M 15/08 (2013.01)] 9 Claims
 
1. A pharmaceutical composition comprising:
a live, purified population of bacteria comprising:
at least three different strains of Dolosigranulum pigrum,
wherein the at least three different strains of Dolosigranulum pigrum provide various bactericidal mechanisms,
wherein the at least three different strains of Dolosigranulum pigrum are a lyophilized population of bacteria,
wherein the at least three different strains of Dolosigranulum pigrum are present in a total amount of at least 10 3 CFU, and
wherein two strains of the at least three different strains of Dolosigranulum pigrum are present individually in an amount of up to about 40% of total CFUs for CFUs present in the live, purified population of bacteria; and
a pharmaceutically acceptable excipient.